ORIGINAL PAPER
Whole-body cryotherapy decreases fibrinolytic activity in blood of patients with rheumatoid arthritis and patients with osteoarthritis
More details
Hide details
Online publication date: 2010-07-02
Reumatologia 2010;48(3):171-176
KEYWORDS
ABSTRACT
In rheumatoid arthritis (RA) there is increased risk of myocardial infarction and other cardiovascular diseases. In active process of RA one can find activation of hemostatic and fibrinolytic system and partialy this can explain more frequent cardiovascular complications. Generally, the whole-body cryotherapy, thought to be safe method in treating RA patients, can potentially change unstable balance in coagulation system. We measured some factors of hemostatic and fibrinolytic system in 46 RA patients and 20 OA patients treated in cryogenic chamber during 10 sesions (in temperature –120°C for 3 min). We found no inhibition of acute phase reactants in RA patients – there was no changes in serum CRP concentration. On the contrary, we found changes in the fibrinolytic system – i.e. lowering of t-PA antigen level in blood and increasing of PAP complexes concentrations (p < 0.05) in blood of RA patients. Lowering of t-PA antigen level and increasing of PAI-1 concentrations (p < 0.05) were seen after 10 sesions of cryotherapy in a group of OA patients. Despite the fact that there was no clinical adverse event observed, we conclude that the therapy of RA patients in cryogenic chamber can disturb hemostatic-fibrinolytic balance and in some patients may lead to thrombosis and cardiovascular events.
REFERENCES (23)
1.
Filipowicz-Sosnowska A. Reumatoidalne zapalenie stawów. W: Choroby wewnętrzne. Szczeklik A (red.). Wyd. I. Medycyna Praktyczna, Kraków 2006; t. II: 1645-1657. .
2.
Del Rincon ID, Williams K, Stern MP, et al. High incidence of cardiocascular events in rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737-2745. .
3.
McEntegart A, Capell HA, Creran D, et al. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid athritis. Rheumatology 2001; 40: 640-644. .
4.
Mercer JB, Osterud B, Tveita T. The effect of short-term cold exposure on risk factors for cardiovascular disease. Thromb Res 1999; 95: 93-104. .
5.
Van der Bom JG, de Maat MP, Bots ML, et al. Seasonal variation in fibrinogen in the Rotterdam Study. Thromb Haemost 1997; 78: 1059-1062. .
6.
Jansky L, Matouskova E, Vavra V, et al. Thermal, cardiac and adrenergic responses to repeated local cooling. Physiol Res 2006; 55: 543-549. .
7.
Zagrobelny Z, Halawa B, Jezierski Cz, Wawrowska A. Wpływ jednorazowego schładzania całego ciała w komorze kriogenicznej na wybrane wskaźniki hemodynamiczne i stężenie hormonów w surowicy u osób zdrowych. Pol Tyg Lek 1993; 48: 303-305. .
8.
Matsuda J, Tsukamoto M, Gohchi K, et al. Effect of total-body cold exposure on plasma concentrations of von Willebrand factor, endothelin-1 and thrombomodulin in systemic lupus erythematosus patients with or without Raynaud´s phenomenon. Acta Haematol 1992; 88: 189-193. .
9.
So AK, Varisco PA, Kemkes-Matthes B, et al. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost 2003; 1: 2510-2515. .
10.
Kopeikina LT, Kamper EF, Koutsoukos V, et al. Imbalance of tissue-type plasminogen activator (t-PA) and its specific inhibitor (PAI-1) in patients with rheumatoid arthritis associated with disease activity. Clin Rheumatol 1997; 16: 254-260. .
11.
Solomon HD, Karlson WE, Rimm BE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303-1307. .
12.
MacKenzie MA. Cold exposure and winter mortality in Europe. Lancet 1997; 350: 590-592. .
13.
Mercer JB. Cold – an underrated risk factor for health. Environ Res 2003; 92: 8-13. .
14.
Bo/kenes L, Alexandersen TE, o/sterud B, et al. Physiological and haematological responses to cold exposure in the elderly. Int J Circumpolar Health 2000; 59: 216-221. .
15.
Wojtecka-Łukasik E, Księżopolska-Pietrzak K, Maśliński S. Chemiluminescencja granulocytów obojętnochłonnych krwi obwodowej chorych na reumatoidalne zapalenie stawów poddanych krioterapii. Reumatologia 1996; 34: 666-667. .
16.
Jonderko G, Rozmus-Kuczia I, Gałaszek Z i wsp. Wpływ krioterapii na wybrane odczyny ostrej fazy u chorych na reumatoidalne zapalenie stawów. Reumatologia 1988; 26: 111-116. .
17.
Sieroń A, Stanek A, Jagodziński L i wsp. Wpływ krioterapii ogólnoustrojowej na wybrane parametry stanu zapalnego u pacjentów z zesztywniającym zapaleniem stawów – doniesienie wstępne. W: Krioterapia miejscowa i ogólnoustrojowa. Zagrobelny Z (red.). Wydawnictwo Medyczne Urban & Partner, Wrocław 2003; 169-175. .
18.
Straburzyńska-Lupa A, Straburzyński G. Fizjoterapia. Wydawnictwo Lekarskie PZWL, Warszawa 2004; 52. .
19.
Księżopolska-Pietrzak K. Miejsce krioterapii w leczeniu chorób narządu ruchu – mechanizmy działania, wskazania i przeciwwskazania. W: Krioterapia miejscowa i ogólnoustrojowa. Zagrobelny Z (red.). Wydawnictwo Medyczne Urban & Partner, Wrocław 2003; 35-41. .
20.
Juhan-Vague I, Morange P, Christine Alessi M. Fibrinolytic function and coronary risk. Curr Cardiol Rep 1999; 1: 119-124. .
21.
Folsom AR Fibrinolytic factors and atherothrombotic events: epidemiological evidence. Ann Med 2000; 32: 85-91. .
22.
Huber K. Defective fibrynolytic states as triggers of myocardial infarction: the cardiologist’s view. Ital Heart J 2001; 2: 646-651. .
23.
Wiman B. Predictive value of fibrinolytic factors in coronary heart disease. Scand J Clin Lab Invest Suppl 1999; 230: 23-31.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (
https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.